The Venture Innovation Program offers Ph.D., MBA, and MD students exposure to life sciences venture capital and start-ups.

Lumira Ventures Fund IV launched the Lumira VIP program for Canadian students to gain experience in life sciences venture capital.

OpSens Medical was acquired by Haemonetics for $345 million, specializing in fiber optic sensing for coronary artery disease treatment.

Gene editing faces challenges like low efficiency and off-target effects, requiring novel approaches for precise disease treatment.

Peter van der Velden shares insights on venture capital and the Canadian health ecosystem with Amol Deshpande.

The MAKO Robot assists in joint replacement surgeries, including total hips, total knees, and partial knees.

Over 300,000 Canadians and 1.5 million Americans live with Type 1 Diabetes, an autoimmune disease requiring lifelong management.

The BC Tech Fund invested in Lumira Capital IV, a healthcare and life science venture fund managed by Lumira Capital.

A Toronto-based company received $1.5 million from the Ontario government for a loyalty-points app promoting healthy living.

Lumira Ventures launched a new website and rebranded from Lumira Capital, marking 30 years in healthcare investment.

Lumira Ventures invests capital to build transformative healthcare companies with potential to improve patient lives.

Lumira Ventures, Canada's largest life sciences venture capital firm, invests in healthcare innovators from early-stage to revenue-generating biotech, biotherapeutics, and medical devices. Headquartered in Toronto, Ontario.

COUR Pharma secures a $50 million Series B funding round. The investment is led by Lumira Ventures and Roche Venture Fund, with additional participation from Sanofi. The company expands its financial backing to advance its pharmaceutical development pipeline.

Jun 2026Lumira VenturesNews article

Contraline secures **$92.5 million in Series B funding** to propel its non-hormonal male contraceptive, **NES/T**, into late-stage clinical trials. The round is co-led by **BVF Partners** and **RA Capital Management**, with participation from **GV (Google Ventures)**, **Lumira Ventures**, and other investors. The company also appoints **Iris van Alderwerelt van Rosenburgh, PhD**, from BVF Partners, to its board.

Jun 2026Lumira VenturesNews article

Lumira Ventures, the Terry Fox Foundation, and the Canadian Cancer Society have completed the first close of the **Cancer Breakthrough Fund**, securing oversubscription within its first year. The fund attracts support from major Canadian cancer charities, impact investors, institutional investors, and family offices. This milestone marks rapid growth in backing for cancer research initiatives.

May 2026Lumira VenturesNews article

Nervonik secures a $52.5 million Series B financing to advance its peripheral nerve stimulation (PNS) technologies. The round includes participation from Lumira Ventures alongside Amzak Health, Elevage Medical Technologies, U.S. Venture Partners, Foothill Ventures, and Shangbay Capital. The company remains in clinical-stage development for next-generation medical devices targeting nerve stimulation therapies.

Apr 2026Lumira VenturesNews article